Effects on immune health

Healthy intestinal microbes = healthy immunity 

LACTOGG’s probiotic helps to establish a strong and vigorous intestinal microbial ecosystem which in turn gives rise to healthy and balanced immunity. 

The presence of the GG probiotic in the intestinal tract promotes the growth of a diverse and vigorous microbial community.  Furthermore, the correct quantity of the dietary fibre, fructooligosaccharide (FOS) which is found in LACTOGG®+ sachets gives it prebiotic benefits as it promotes the growth of other good bacteria such as bifidobacteria.

Premature infants given GG probiotic and probiotics for their first 2 months of life had less frequent respiratory tract infection, especially those caused by viruses, during their first year of life. Those non-GG babies did not experience this beneficial effect.  This study shows that using the GG probiotic and prebiotics to establish the microbes which colonise babies very early in life can benefit their developing immune system.

Clinical studies have shown how LACTOGG®’s probiotic’s boost in immunity results in significant benefits.

Examples of these research findings are:

• Mothers who consumed GG probiotic during pregnancy were found to have GG bacterial DNA in the amniotic fluid and placenta. When the babies who were born to these “GG” mothers were tested shortly after birth, their immunity showed higher maturity than the other non-GG babies.

• Infants who took GG probiotic were found to have increased number and maturation of their immune cells which manufacture antibodies.

Comparison of the number of antibody-secreting cells in babies at 1 year old.  GG probiotic increases cells which secrete antibodies M, A and G[Rinne et al. 2005]

• Babies who were exposed to GG probiotic during pregnancy and in the first 6 months of life had 50% less chance of developing allergic eczema.  The “GG” babies had higher levels of immune regulatory factors which reduced allergic inflammation.

• Allergy sufferers such as those with allergic eczema, cow milk allergy and allergic nose, experienced significant improvement in their allergic conditions when they were given the GG probiotic.  Their immune system also showed less allergic hallmarks.

• Infants with proven cow milk allergy recover from their allergy faster if they were given GG probiotic daily in the first year of life.

• Children given GG probiotic had less chance of contracting intestinal infections (gastroenteritis) and recovered faster from gut infections.

• Infants, toddlers and older children were noted to fight infections better and needed less antibiotics.  This improvement in immunity continued to be apparent over long periods of time.

Total number of courses of antibiotic (macrolides) used by children over 3 years. Dotted line marks the end of 7 months of dally consumption of GG probiotic.  The GG group used 48% less antibiotic over the 3 years compared to those not given the probiotic. [Korpela et al. 2016]

• Adults also showed improved ability to fight infections, such as lung infections and traveller’s diarrhoea.

• It has been used in hospitals to clear superbugs from the intestinal tract in children and adults.

• Children and adults suffering from intestinal inflammation conditions were found to have reduced inflammation after consuming the GG probiotic.

 Amount of faecal calprotectin (an indicator of intestinal inflammation) is lowered after Lactobacillus GG is consumed. [Bruzzese E et al. 2014]

• The immune response to vaccinations was noted to be enhanced significantly when people were taking the GG probiotic during the time of vaccination.

• Drinking alcohol sets-up much inflammation in the gastrointestinal tract and liver which progresses to liver damage.  Taking the GG probiotic prevents and reverses liver inflammation and damage as it increases Treg cells and reduces the number of immune cells responsible for intestinal and liver inflammation.

LACTOGG®’s ability to ‘talk’ to our immune system means that it can ‘educate’, mature, stimulate and ‘balance’ our immune system.

We can make use of LACTOGG® capsules or LACTOGG®+ sachets to maintain long term, healthy stimulation of our immunity.

How should LACTOGG® be taken?

Babies, children and adults:

At least 1 capsule or 1 sachet a day


Cox MJ et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS ONE 2010;5(1):e8745

Luoto R et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. J Allergy Clin Immunol 2014;133:405-13

Rautava S et al. Probiotics modulate host-microbe interaction in the placenta and fetal gut: A randomized, double-blind, placebo-controlled trial. Neonatology 2012;102:178-184

Kalliomaki M et al. Probiotic in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079

Marschan E et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008;38:611-618

Viljanen M et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60:494-500

Isolauri E et al. Probiotics in management of atopic eczema. Chin Exp Allergy 2000;30:1604-1610

Piirainen L et al. Effect of Lactobacillus rhamnosus GG on rBet v1 and rMal d1 specific IgA in the saliva of patients with birch pollen allergy. Ann Allergy Asthma Immunol 2008;100(4):338-342

Kawase M et al. Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol 2009;128(3):429-434

Majamaa H et al. Probiotic: A novel approach in the management of food allergy. J Allergy Clin Immunol 1997;99:179-185

Pohjavuori E et al. Lactobacillus GG effect in increasing IFN-ɣ production in infants with cow's milk allergy. J Allergy Clin Immunol 2004:114:131-136

Berni Canani R et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: A randomized trial. J Allergy Clin Immunol 2012;129(2):580-581

Berni Canani R et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335(7615):340

Kaila M et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human L. strain. Pediatr Res1992;32(2):141-144

Guandalini S et al. Lactobacillus GG admin in oral rehydration solution to children with acute diarrhoea: A Multicenter European Trial. J Pediatr Gastrpenterol Nutr 2000;30(1):54-60

Oberhelman R et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999;134:15-20  

Szajewska H et al. Efficacy of Lactobacillus GG in prevention of  nosocomial diarrhea in infants. J Pediatr 2001;138:361-365

Korpela K et al. Lactobacillus rhamnosus GG intake modifies preschool children's intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS ONE 2016

Hojsak I et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010;125(5):e1171-7

Hatakka K et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001:322(7298):1327

Hojsak I et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day car centers: A randomized, double-blind, placebo-controlled trial. Clin Nutr 2009

Kukkonen K et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Paediatrics 2008;122:8-12

Morrow LE et al. Probiotic prophylaxis of ventilator-associated pneumonia. A blinded, randomized, controlled trial. Am J Resp Crit Care Med 2010;182:1058-1064

Oksanen PJ  et al. Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med 1990;22:53-56

Szachta P et al. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant entercocci in colonized children. J Clin Gastroenterol 2011:45(10):872-877

Manley KJ et al. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007;186(9):454-457

Cheng VCC et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis 2014;14-514

Bruzzese Eet al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: A randomised clinical trial. PLoS ONE 2014;9(2):e87796

Malin M et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-145

Gosselink MP et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47(6):876-884

Zocco MA et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther 2006;23:1567-1574

Davidson LE et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomised double-blind placebo controlled trial. Eur J Clin Nutr 2011;65:501-507

de Vrese M et al. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur J Nutr 2005;44(7):406-413

Chen R-C et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett 2016;241:103-110

Bajaj JS et al. Randomized clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014;39(10):1113-1125

Hammes TO et al. Lactobacillus rhamnosus GG reduces hepatic fibrosis in a model of chronic liver disease in rats. Nutr Hosp 2017;34(3):702-709

Hong Kong Special Administrative Region PaediHealth (HK) Ltd. (1286528) 18th Floor, United Centre, 95 Queensway
Hong Kong
Tel: +852 3486 7233     Fax: +852 3486 3723
China Guangzhou Synthgensys Biotechnology Co. Ltd. Unit 501-1, No. 7, Spiral 4 Road, Guangzhou International Bioisland, P R China Tel: +0757 26616888     Fax: +0757 26382288 Brunei Am Prolife Company (P20017787) P.O. Box 31, Jalan Gadong
BE3919, Brunei Darulssalam
Tel: +673 7335566
Email: amprolifebn@gmail.com
Singapore ProbioCare Pte. Ltd. (201603757R) 32 Ean Kiam Place
Singapore 429119
Tel: +65 6255 5592     Fax: +65 6255 5563
Malaysia ProbioCare Sdn. Bhd. (1124987-P) 122 Jalan Ipoh
51200 Kuala Lumpur
Malaysia Tel: +603 2011 1223     Fax: +603 2094 7723

Thailand Paedicare (Thailand) Co. Ltd 973 President Tower, Level 14
Unit D and E (1423) Ploenchit Road, Lumpini,
Pathumwan, Bangkok 10330, Thailand
Tel: +66 99 2828338
FOLLOW US websiteusers@lactogg.com Brochures Privacy Policy Glossary
Copyright 2017-2022 Guangzhou Synthgensys Biotechnology Co.Ltd.